Embark on a detailed exploration of the landscape of PD1/PD-L1 immune checkpoint inhibitors in the United States and Europe. This comprehensive guide provides invaluable insights for sponsors looking to design effective clinical trials in oncology and formulate strategic early development plans.

This white paper explores the transformative impact of PD1/PD-L1 immune checkpoint inhibitors across a range of solid tumors, gaining a deeper understanding of FDA and EMA-approved indications.

Download our white paper to discover:

• Strengths of PD1/PD-L1 inhibitors across diverse cancers, understanding their mechanisms and citing successful clinical outcomes.
• Challenges and limitations, including immune-related adverse events and resistance issues.
• Future potential of combining immune checkpoint inhibitors with other anti-cancer agents, drawing on data from current clinical studies and trials.